English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Association between depression subtypes and response to repeated‐dose intravenous ketamine

Wang, C., Zhou, Y., Zheng, W., Liu, W., Zhan, Y., Li, H., et al. (in press). Association between depression subtypes and response to repeated‐dose intravenous ketamine. Acta Psychiatrica Scandinavica, Epub ahead. doi:10.1111/acps.13096.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/21.11116/0000-0004-9B48-D Version Permalink: http://hdl.handle.net/21.11116/0000-0004-A949-C
Genre: Journal Article

Files

show Files

Locators

show
hide
Description:
-

Creators

show
hide
 Creators:
Wang, C, Author
Zhou, Y, Author
Zheng, W, Author
Liu, W, Author
Zhan, Y, Author
Li, H, Author
Chen, L, Author
Zhang, B, Author
Walter, M, Author              
Li, M1, 2, Author              
Li, MD, Author
Ning, Y, Author
Affiliations:
1Max Planck Institute for Biological Cybernetics, Max Planck Society, ou_1497794              
2Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society, ou_1497796              

Content

show
hide
Free keywords: -
 Abstract: Objective About half or more of treatment‐resistant depressed patients do not respond to ketamine, and few clinical predictors to gauge the most likely antidepressant response have been proposed. We explored whether depression subtypes are associated with response to ketamine. Methods Ninety‐seven participants with depression were administered six repeated‐dose intravenous ketamine and assessed for depression (Montgomery‐Åsberg Depression Rating Scale, MADRS), anxiety (Hamilton Anxiety Rating Scale, HAMA), and suicidal ideation (Beck Scale for Suicidal Ideation, SSI) at baseline, 24 hours after each infusion, and 2 weeks after the whole treatment. Participants were classified by melancholic/anxious subtype. Individuals who met criteria for neither or both subtypes were classified separately, resulting in four mutually exclusive groups. Results Patients with melancholic or melancholic‐anxious features were less likely to respond (e.g. day 13, melancholic‐anxious vs. anxious, OR 0.138, 95% CI 0.032–0.584, p = 0.007) or remit (e.g. day 26, melancholic vs. no subtype, OR 0.182, 95% CI 0.035–0.960, p = 0.045) and took longer to achieve response/remission than those with anxious or no subtype features. Faster HAMA score reductions were observed in patients with anxious or melancholic‐anxious features, and faster SSI score reductions were observed among those with melancholic‐anxious features. Conclusions Our study shows promising results for ketamine as a novel antidepressant preferentially for the treatment of non‐melancholic or anxious depression.

Details

show
hide
Language(s):
 Dates: 2019-09
 Publication Status: Accepted / In Press
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Identifiers: DOI: 10.1111/acps.13096
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Acta Psychiatrica Scandinavica
  Other : Acta Psychiatr. Scand.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Copenhagen : Munksgaard.
Pages: - Volume / Issue: Epub ahead Sequence Number: - Start / End Page: - Identifier: ISSN: 0001-690X
CoNE: https://pure.mpg.de/cone/journals/resource/954927587269